Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine

Abstract

Cases of carditis after the use of a messenger RNA (mRNA) COVID-19 vaccine have been reported in various populations worldwide. However, few studies have directly evaluated this association. Furthermore, it is unclear whether this potential risk involves vaccine platforms other than mRNA vaccines. This case–control study from Hong Kong aimed to examine the association between COVID-19 vaccination with an mRNA vaccine or an inactivated virus vaccine and the subsequent risk for carditis. The results of this study could be useful for public health policymakers to weigh the risk and benefit of population-wide COVID-19 vaccination programs.

Lack of inflammatory bowel disease flare-up following two-dose BNT162b2 vaccine: a population-based cohort study

“…However, the effects of COVID-19 vaccine on IBD activity, particularly severe flare resulting in hospitalisation, and the interplay with the use of immunotherapy remain unknown. To address these questions, we analysed the territory-wide electronic medical records with vaccination linkage database in Hong Kong [2][3][4][5][6][7] to examine the association between BNT162b2 vaccination and IBD flare.…”

Autoimmune conditions following mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccination: A descriptive cohort study among 1.1 million vaccinated people in Hong Kong

“…EMRs from the HA were linked with the DH vaccination records using de-identified non-reversible pseudo-ID to protect patient privacy. The database has been use for several COVID-19 vaccine safety assessment in HK [ 8 , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] ].…”

Case Report: Disappearance of Late Gadolinium Enhancement and Full Functional Recovery in a Young Patient With SARS-CoV-2 Vaccine-Related Myocarditis

“…Recently, a couple of studies demonstrated acute myocarditis in previously healthy young male patients following receipt of mRNA SARS-CoV-2 vaccine ( 1 – 3 ). The acute onset of chest pain 3–5 days after the administration of the second or third dose of the vaccine is a typical feature, reported in the reported cases, suggesting an immune-mediated mechanism.…”